KOSDAQBiotech & Pharma468530

Proteina

₩50,700▼ 1.17%2026-10-02 close

Market Cap

₩569.7B

Turnover

₩6.8B

Volume

140,000 shares

Shares out.

11.1M

PER

—

PBR

13.5×

EPS

-₩1,120

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Proteina Shifts Its Business Axis Toward Drug Discovery

Proteina, which listed as a protein-protein interaction (PPI) analysis platform company, is expanding into proprietary and co-developed antibody drug discovery, but revenue has repeatedly fallen short of its IPO-stage targets while quarterly losses have kept widening.

1
2025 revenue rose to KRW 2.95 billion from KRW 2.3 billion a year earlier, but operating loss widened to KRW 11.37 billion and net loss to KRW 9.01 billion.
2
Revenue fell to KRW 168.6 million in Q1 2026 before recovering to KRW 349.3 million in Q2, while the combined net loss attributable to owners over the most recent four quarters (Q3 2025-Q2 2026) reached roughly KRW 12.0 billion.
3
The company projected KRW 6.6 billion in 2025 revenue and KRW 14.8 billion in 2026 revenue at IPO, but media reports say actual results have fallen well short of these targets.
4
Through its investment in newly formed ABX Biosciences for de novo antibody design and a joint government-funded project with Samsung Bioepis and Seoul National University, the company is expanding from a service-revenue model toward drug discovery and licensing.
5
Due to continued losses, no price-to-earnings ratio can be calculated, while the price-to-book ratio trades at a premium to net asset value.

Business structure

Proteina was founded in 2015 as a KAIST faculty spin-off and has commercialized the SPID platform, which analyzes protein-protein interactions (PPI) at the single-molecule level.

SPID is based on Pi-chip technology that can detect target proteins in complex, unpurified samples, and the company states it achieves up to 100 times higher sensitivity than conventional immunoblot or ELISA methods.

The company's business is organized around three pillars: the clinical biomarker analysis solution 'PPI PathFinder,' the antibody optimization and design solution 'PPI Landscape,' and the instrument-embedded product 'SPID Systems.' PathFinder has historically been the main revenue driver, generating roughly KRW 2.1 billion, or about 75% of total revenue in 2024, from multiple clients including global pharmaceutical companies.

In terms of competitive positioning, Meso Scale Discovery, Quanterix, Olink, and SomaLogic are cited as competitors in proteomics analysis services, while Sartorius and Danaher are named in antibody engineering and optimization.

More recently, the company has been shifting from a services-centered model toward proprietary and co-developed drug discovery, formally adding drug development, technology licensing, and AI-based drug discovery solutions to its corporate purpose at a shareholders' meeting.

Its proprietary pipeline includes 'PRT-1309,' a long-acting GIPR antagonist antibody targeting obesity, and 'PRT-101,' an osteoarthritis treatment candidate, both of which have had preclinical data disclosed at scientific conferences.

In 2026, the company invested roughly KRW 3.4 billion to become the largest shareholder of newly established ABX Biosciences for de novo antibody design commercialization, with that entity taking charge of commercializing the AI antibody design platform 'AbGPT-3D' developed under a Ministry of Science and ICT national R&D project.

This restructuring reflects a mid-to-long-term strategy of diversifying revenue across analysis services, diagnostics, co-development, and proprietary pipeline licensing.

Earnings trend

Quarterly revenue · Operating profit

25Q2₩600M-₩2.9B25Q3₩300M-₩4.4B25Q4₩200M-₩4.7B26Q1₩300M-₩4B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩2.3B-₩9.1B2024₩3B-₩11.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	—	—
2025Q3	₩600M	-₩2.9B	−506.4%
2025Q4	₩300M	-₩4.4B	−1295.4%
2026Q1	₩200M	-₩4.7B	−2795.5%
2026Q2	₩300M	-₩4B	−1132.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2024	₩2.3B	-₩9.1B	-₩5.7B	−396.5%	−36.4%	14.0%
2025	₩3B	-₩11.4B	-₩9B	−385.2%	−31.8%	11.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated 2025 revenue rose to KRW 2.95 billion from KRW 2.3 billion in 2024, but operating loss widened from KRW 9.12 billion to KRW 11.37 billion, and net loss expanded from KRW 5.73 billion to KRW 9.01 billion.

The operating margin improved slightly to -385.2% in 2025 from -396.5% the prior year, but losses still dwarf the revenue base.

On a quarterly basis, revenue fell from KRW 582 million in Q3 2025 to KRW 343 million in Q4, then to KRW 169 million in Q1 2026, before recovering to KRW 349 million in Q2 2026, reflecting the volatility inherent in a service-revenue model.

Operating loss similarly widened from KRW 2.95 billion in Q3 2025 to KRW 4.45 billion in Q4 and KRW 4.71 billion in Q1 2026, before narrowing slightly to KRW 3.96 billion in Q2.

Over the most recent four quarters (Q3 2025 through Q2 2026), the combined net loss attributable to owners reached approximately KRW 12.0 billion (KRW 11,999,933,630), indicating that the annualized loss scale has grown larger than before.

Operating cash flow also deteriorated, with outflows increasing from KRW 6.08 billion in 2024 to KRW 8.07 billion in 2025, showing that R&D and personnel spending has outpaced revenue growth.

Total equity increased from KRW 15.76 billion in 2024 to KRW 28.37 billion in 2025, largely reflecting IPO proceeds, while the debt ratio remains low at 11.9%.

However, the gap between IPO-stage revenue guidance and actual results has recurred: actual 2025 revenue fell short of the KRW 6.6 billion target by more than half, and reports indicate that first-half 2026 revenue represented only a fraction of the KRW 14.8 billion full-year 2026 target. The pace of accumulated losses is a variable that could be linked to future funding needs.

Industry analysis

The PPI analysis and biomarker market is one where global pharmaceutical companies are increasing investment to quantify target binding of drug candidates and improve clinical success rates, and Proteina competes here against Meso Scale Discovery, Quanterix, Olink, and SomaLogic.

In antibody optimization and design, it competes with large instrument and service companies such as Sartorius and Danaher, and in AI-driven drug discovery, with startups such as BigHat Biosciences and Nebula.

The global biotech industry has recently seen intensifying competition in AI-based antibody and protein design, with high-quality PPI data emerging as a key resource for training AI models.

The company states that three researchers using its platform can analyze 3,000 to 5,000 antibodies per week, which it describes as faster than a peer company that requires 100 researchers two weeks to analyze 500 antibodies.

In the obesity treatment market, suppressing weight regain—a limitation often cited for GLP-1 class drugs—is emerging as a new competitive axis, and the company's PRT-1309 is aimed at this point.

Domestically, the company is entering the AI antibody design ecosystem through participation in a joint national R&D project with a major biosimilar and drug developer, Samsung Bioepis.

However, this market remains at an early stage with limited cases of clinical validation and large-scale licensing deals, and competition is expected to intensify as multiple domestic and international players pursue similar business models.

Outlook

At its IPO, the company presented a goal of achieving profitability by 2027 through the full-scale commercialization of the PPI Landscape business.

To that end, it is realigning strategy toward strengthening drug discovery capabilities and has formally added drug development, technology licensing, and AI-based drug discovery solutions to its articles of incorporation.

Its proprietary pipeline candidates PRT-1309 (a GIPR antagonist antibody) and PRT-101 (an osteoarthritis treatment candidate) are undergoing external validation, having had preclinical data presented at the American Diabetes Association (ADA) and European Alliance of Associations for Rheumatology (EULAR) conferences, respectively.

In 2026, the company became the largest shareholder of ABX Biosciences to commercialize de novo antibody design, with that entity handling commercialization of the AI design platform AbGPT-3D, a deliverable of a Ministry of Science and ICT national project.

Through a KRW 47 billion joint national R&D project with Samsung Bioepis and Seoul National University, the goal is to develop 10 AI-designed antibody drug candidates by 2027, with one targeted for a Phase 1 IND submission. The launch of a Venetoclax companion diagnostic product via acquisition of a U.S.

CLIA-certified lab was also presented as a 2026 target, though specific disclosures on its progress have not yet been confirmed.

However, the revenue targets presented at IPO (KRW 6.6 billion for 2025 and KRW 14.8 billion for 2026) have shown considerable gaps versus actual results, making the timing and pace at which the drug discovery pivot's results materialize a key variable for future earnings visibility.

Valuation

PER

—

PBR

13.5×

ROE

-68.1%

EPS

-₩1,120

BPS

₩2,281

Dividend per share

₩0

Proteina has yet to generate net income since its listing, leaving it in a range where a price-to-earnings ratio cannot be calculated. By contrast, its price-to-book ratio trades at a substantial premium to net asset value, even though total equity has grown considerably since the early listing period.

This suggests the market is placing greater weight on the drug discovery pivot, national R&D projects, and global partnerships as a future growth story rather than on current revenue and earnings.

No dividends are being paid, indicating that capital is being prioritized toward R&D investment and business expansion rather than shareholder returns.

Looking at the multi-year earnings trend, revenue has grown modestly while loss size has also continued to expand, meaning that until a clear turn from loss to profit is confirmed, the market's valuation assessment is likely to remain sensitive to business-performance news.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Platform Technology and Global Client Track Record

The company states that its SPID platform can detect target proteins without purification and achieves up to 100 times higher sensitivity than conventional methods. In terms of throughput, it also presents the ability to analyze large numbers of antibodies with a small team as a competitive advantage.

A track record of multiple clinical sample analysis service contracts with multinational pharmaceutical companies is cited as supporting evidence for this technology.

Revenue Model Diversification Into Drug Discovery and Diagnostics

Through its proprietary pipeline (PRT-1309, PRT-101) and investment in newly formed ABX Biosciences for de novo antibody design, the company is expanding beyond service revenue into technology licensing, co-development, and diagnostics revenue.

Participation in the KRW 47 billion national R&D project with Samsung Bioepis and Seoul National University can be viewed as an opportunity to secure research funding while accumulating collaborative experience with major partners.

Low Financial Burden Following IPO Capital Inflow

IPO proceeds increased total equity from KRW 15.76 billion in 2024 to KRW 28.37 billion in 2025, while the debt ratio remains low at 11.9%. This can be viewed as giving the company room to continue R&D and business restructuring without immediate financial pressure.

Bear factors

Recurring Shortfalls Against Revenue Targets

Actual 2025 revenue fell short of the KRW 6.6 billion target by more than half, and reports indicate first-half 2026 revenue represented only a fraction of the KRW 14.8 billion full-year target.

The structural characteristic of service revenue being dependent on client clinical and research schedules is cited as the background for these recurring forecast gaps.

Widening Losses and Cash Burn

Operating loss widened from KRW 9.12 billion in 2024 to KRW 11.37 billion in 2025, and operating cash outflow expanded from KRW 6.08 billion to KRW 8.07 billion.

The combined net loss attributable to owners over the most recent four quarters also reached roughly KRW 12.0 billion, and no clear sign of loss reduction has yet been confirmed.

Funding and Dilution Concerns

The company's expansion of its mezzanine issuance capacity and addition of an M&A purpose to its articles of incorporation implies possible future fundraising or equity dilution. Concerns about overhang from lock-up releases after listing have also been raised in past brokerage commentary.

Risk factors

Earnings/Business Model Risk

Revenue is heavily dependent on contract schedules with a small number of large clients, resulting in significant quarterly volatility and recurring gaps versus IPO-stage guidance.

As the drug discovery pivot progresses, delays in revenue recognition from reprioritization away from existing service revenue cannot be ruled out.

Funding and Financial Risk

R&D and personnel spending, large relative to revenue, has continued, with operating cash outflow expanding each year. The expansion of mezzanine issuance capacity suggests future equity dilution possibilities cannot be ruled out.

Pipeline and Business Transition Risk

The proprietary antibody drug pipeline (PRT-1309, PRT-101) remains at the preclinical stage, leaving clinical entry and licensing outcomes uncertain. The execution timeline for previously announced plans, such as entering the diagnostics business through a U.S. CLIA lab acquisition, has also not yet been concretely confirmed.

What to watch next

Mid-November 2026
The Q3 2026 report will show whether revenue is recovering, whether the operating loss trend is narrowing, and how the cost structure is changing amid the drug discovery pivot.
Q4 2026
It is worth checking whether the company completes the U.S. CLIA lab acquisition and launches the Venetoclax companion diagnostic product, both of which were presented as 2026 targets at IPO.
Through 2027
Interim progress on the KRW 47 billion national R&D project with Samsung Bioepis and Seoul National University, including the status of AI-designed antibody candidates and whether the Phase 1 IND submission goal is met, should be monitored.
Second half of 2026 through 2027
Commercialization milestones for the AbGPT-3D de novo antibody design platform via ABX Biosciences, as well as any external partnership agreements, should be watched.
Upon future disclosures
Should disclosures emerge on mezzanine issuance or M&A-related fundraising, the resulting equity dilution and changes in financial structure should be reviewed.

Overall view

Proteina is expanding from its proprietary protein-protein interaction analysis platform into proprietary and co-developed antibody drug discovery and diagnostics, announcing a series of significant partnerships including the national R&D project with Samsung Bioepis and Seoul National University and its investment in ABX Biosciences.

Financially, however, losses have continued to widen each year, with 2025 revenue of KRW 2.95 billion accompanied by an operating loss of KRW 11.37 billion and a net loss of KRW 9.01 billion, while the combined net loss attributable to owners over the most recent four quarters reached roughly KRW 12.0 billion.

The gap between IPO-stage revenue targets and actual results has recurred through 2025 and the first half of 2026, making the timing and magnitude at which the drug discovery pivot materializes in revenue and earnings a key variable going forward.

Total equity has grown on IPO proceeds and the debt ratio remains low, but operating cash outflow has expanded each year, and funding options such as an expanded mezzanine issuance capacity and an added M&A purpose have already been put in place, which also merits attention.

Valuation currently sits in a loss-making range where a price-to-earnings ratio cannot be calculated, while the price-to-book ratio trades at a premium to net asset value, indicating the market is assigning substantial value to the future growth narrative.

Upcoming Q3 earnings, progress on the CLIA lab and companion diagnostic commercialization, interim results from the national R&D project, and any further fundraising disclosures will be the next checkpoints for assessing both business direction and financial burden together.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.